"10.1371_journal.pone.0110437","plos one","2014-10-23T00:00:00Z","Anne Sofie Laulund; Mads Nybo; Thomas Heiberg Brix; Bo Abrahamsen; Henrik Løvendahl Jørgensen; Laszlo Hegedüs","Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark; Odense Patient Data Explorative Network OPEN, University of Southern Denmark, Odense, Denmark; Institute of Clinical Research, Odense, Denmark; Research Centre for Ageing and Osteoporosis, Department of Medicine M, Glostrup Hospital, Copenhagen, Denmark; Department of Clinical Biochemistry, Bispebjerg Hospital, Copenhagen, Denmark","Conceived and designed the experiments: ASL MN BA HLJ THB LH. Performed the experiments: ASL MN BA HLJ THB LH. Analyzed the data: ASL MN BA HLJ THB LH. Contributed reagents/materials/analysis tools: ASL MN BA HLJ THB LH. Wrote the paper: ASL MN BA HLJ THB LH.","The authors have the following interests. Bo Abrahamsen has the following interests: Grants from or conducted trials for Novartis, Nycomed/Takeda and Amgen; advisory board member Nycomed/Takeda, Merck and Amgen; and speakers fees from Nycomed/Takeda, Amgen, Merck, Eli Lilly. Laszlo Hegedüs is a consultant for and is supported by an unrestricted grant from the Novo Nordisk Foundation. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","10","Anne Sofie Laulund","ASL",6,TRUE,6,6,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
